RHJA
AKBA icon

Rice Hall James & Associates’s Akebia Therapeutics AKBA Stock Holding History

Rice Hall James & Associates’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-513,292
Closed -$368K – 266
2022
Q1 		$368K Buy
513,292
+27,072
+6% +$57.9K 0.01% 261
2021
Q4 		$1.1M Sell
486,220
-79,806
-14% -$218K 0.04% 242
2021
Q3 		$1.63M Buy
566,026
+13,050
+2% +$37.3K 0.06% 229
2021
Q2 		$2.1M Sell
552,976
-24,996
-4% -$84.1K 0.07% 206
2021
Q1 		$1.96M Sell
577,972
-968,197
-63% -$3.49M 0.06% 220
2020
Q4 		$4.33M Sell
1,546,169
-32,910
-2% -$96.1K 0.15% 111
2020
Q3 		$3.96M Buy
1,579,079
+206,191
+15% +$1.81M 0.16% 110
2020
Q2 		$18.6M Sell
1,372,888
-34,276
-2% -$355K 0.8% 39
2020
Q1 		$10.7M Buy
1,407,164
+8,543
+0.6% +$66.5K 0.6% 49
2019
Q4 		$8.84M Sell
1,398,621
-85,516
-6% -$406K 0.3% 109
2019
Q3 		$5.82M Sell
1,484,137
-9,933
-0.7% -$42.6K 0.21% 115
2019
Q2 		$7.23M Sell
1,494,070
-51,612
-3% -$294K 0.24% 117
2019
Q1 		$12.7M Buy
1,545,682
+324,184
+27% +$2.22M 0.41% 93
2018
Q4 		$6.75M Buy
1,221,498
+1,181,278
+2,937% +$9.24M 0.25% 112
2018
Q3 		$355K Buy
+40,220
New +$360K 0.01% 281

Other funds holding AKBA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Rice Hall James & Associates's AKBA Position: Q2 2022 in Review

Rice Hall James & Associates sold out of Akebia Therapeutics (AKBA) in Q2 2022, closing a stake of 513,292 shares — an estimated $368K sold.

Rice Hall James & Associates first reported a position in AKBA in Q3 2018 and held it in 15 quarters. The position peaked at $18.6M in Q2 2020. 96 funds tracked by Wall St. Rank hold AKBA as of Q2 2022.

  • Rice Hall James & Associates reported no remaining Akebia Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Rice Hall James & Associates sold 513,292 Akebia Therapeutics shares in Q2 2022, an estimated $368K.
  • Rice Hall James & Associates first reported a position in Akebia Therapeutics in Q3 2018 and held it in 15 quarters.
  • Rice Hall James & Associates's Akebia Therapeutics position peaked at $18.6M in Q2 2020.
  • 96 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2022.

Based on Rice Hall James & Associates's 13F filing for Q2 2022, filed 8 Aug 2022.